386 studies found for:    "Myelodysplastic/myeloproliferative disease"
Show Display Options
Rank Status Study
1 Recruiting A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis
Conditions: Leukemia, Myelocytic, Acute;   Myelodysplastic Syndrome (MDS);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myelofibrosis
Intervention: Drug: CPI-0610
2 Terminated
Has Results
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Conditions: Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: alemtuzumab;   Biological: graft-versus-tumor induction therapy;   Biological: rituximab;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation
3 Terminated Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total body irradiation
4 Completed Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
Conditions: Brain Tumor;   Central Nervous System Tumors;   Cachexia;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: cyproheptadine hydrochloride;   Drug: megestrol acetate
5 Terminated Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Conditions: Graft Versus Host Disease;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: alemtuzumab;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: methotrexate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
6 Completed Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Conditions: Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Secondary Myelofibrosis
Interventions: Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
7 Active, not recruiting Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous/Nonmalignant Condition
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: sirolimus;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
8 Completed Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: ganciclovir;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation
9 Active, not recruiting Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: sargramostim;   Drug: bexarotene;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: biopsy
10 Completed Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Conditions: Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions: Biological: alemtuzumab;   Drug: methylprednisolone;   Drug: prednisone;   Other: flow cytometry;   Other: immunologic technique;   Other: pharmacological study
11 Completed Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
12 Withdrawn Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Conditions: Anemia;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: filgrastim;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
13 Completed Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: clofarabine;   Drug: cyclophosphamide
14 Terminated Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Conditions: Chronic Myeloproliferative Disorders;   Diamond-blackfan Anemia;   Fanconi Anemia;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: filgrastim;   Drug: melphalan;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Procedure: radiation therapy;   Procedure: umbilical cord blood transplantation
15 Completed Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Psychosocial Effects of Cancer and Its Treatment
Interventions: Procedure: psychosocial assessment and care;   Procedure: Quality of Life Assessments
16 Completed Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: dexamethasone;   Drug: thalidomide
17 Completed Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
Conditions: Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: graft versus host disease prophylaxis/therapy;   Procedure: allogeneic bone marrow transplantation;   Procedure: in vitro-treated bone marrow transplantation
18 Completed Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: filgrastim;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
19 Terminated G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Sarcoma
Interventions: Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Procedure: allogeneic bone marrow transplantation;   Radiation: radiation therapy
20 Completed Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin;   Biological: etanercept

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years